

Giuseppe Badalamenti

List of Publications by Year in descending order

Source: [//exaly.com/author-pdf/3582509/publications.pdf](https://exaly.com/author-pdf/3582509/publications.pdf)

Version: 2024-02-01

55
papers

1,418
citations

299104

20
h-index

306047

35
g-index

76
all docs

76
docs citations

76
times ranked

2296
citing authors

#	ARTICLE	IF	CITATIONS
1	Immunological Aspects of Von Hippel-Lindau Disease: A Focus on Neuro-Oncology and Myasthenia Gravis. <i>Diagnosics</i> , 2023, 13, 144.	2.8	5
2	Exploring the Dynamic Crosstalk between the Immune System and Genetics in Gastrointestinal Stromal Tumors. <i>Cancers</i> , 2023, 15, 216.	3.9	8
3	CT and MR Imaging of Retroperitoneal Sarcomas: A Practical Guide for the Radiologist. <i>Cancers</i> , 2023, 15, 2985.	3.9	8
4	The Impact of O6-Methylguanine-DNA Methyltransferase (MGMT) Promoter Methylation on the Outcomes of Patients with Leiomyosarcoma Treated with Dacarbazine. <i>Cells</i> , 2023, 12, 1635.	4.3	1
5	Adjuvant Imatinib in Patients with GIST Harboring Exon 9 KIT Mutations: Results from a Multi-institutional European Retrospective Study. <i>Clinical Cancer Research</i> , 2022, 28, 1672-1679.	7.3	21
6	Weekly cisplatin with or without imatinib in advanced chordoma: A retrospective case-series analysis from the Italian Rare Cancers Network. <i>Cancer</i> , 2022, 128, 1439-1448.	4.1	5
7	Deep Learning Networks for Automatic Retroperitoneal Sarcoma Segmentation in Computerized Tomography. <i>Applied Sciences (Switzerland)</i> , 2022, 12, 1665.	2.6	11
8	Safety and effectiveness of gemcitabine for the treatment of classic Kaposi's sarcoma without visceral involvement. <i>Therapeutic Advances in Medical Oncology</i> , 2022, 14, 175883592210868.	3.4	0
9	Selinexor in Advanced, Metastatic Dedifferentiated Liposarcoma: A Multinational, Randomized, Double-Blind, Placebo-Controlled Trial. <i>Journal of Clinical Oncology</i> , 2022, 40, 2479-2490.	5.3	23
10	The Evolving Scenario in the Assessment of Radiological Response for Hepatocellular Carcinoma in the Era of Immunotherapy: Strengths and Weaknesses of Surrogate Endpoints. <i>Biomedicines</i> , 2022, 10, 2827.	3.3	4
11	Clinical Potential of Circulating Cell-Free DNA (cfDNA) for Longitudinally Monitoring Clinical Outcomes in the First-Line Setting of Non-Small-Cell Lung Cancer (NSCLC): A Real-World Prospective Study. <i>Cancers</i> , 2022, 14, 6013.	3.9	16
12	Not all <i>KIT</i> 557/558 codons mutations have the same prognostic influence on recurrence-free survival: breaking the exon 11 mutations in gastrointestinal stromal tumors (GISTs). <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592110497.	3.4	4
13	Type and Gene Location of KIT Mutations Predict Progression-Free Survival to First-Line Imatinib in Gastrointestinal Stromal Tumors: A Look into the Exon. <i>Cancers</i> , 2021, 13, 993.	3.9	18
14	Trabectedin for Patients with Advanced Soft Tissue Sarcoma: A Non-Interventional, Retrospective, Multicenter Study of the Italian Sarcoma Group. <i>Cancers</i> , 2021, 13, 1053.	3.9	16
15	Prognostic Role of Plasma PD-1, PD-L1, pan-BTN3As and BTN3A1 in Patients Affected by Metastatic Gastrointestinal Stromal Tumors: Can Immune Checkpoints Act as a Sentinel for Short-Term Survival?. <i>Cancers</i> , 2021, 13, 2118.	3.9	25
16	Assessment of morphological CT imaging features for the prediction of risk stratification, mutations, and prognosis of gastrointestinal stromal tumors. <i>European Radiology</i> , 2021, 31, 8554-8564.	4.7	20
17	Prevalence and Spectrum of Germline BRCA1 and BRCA2 Variants of Uncertain Significance in Breast/Ovarian Cancer: Mysterious Signals From the Genome. <i>Frontiers in Oncology</i> , 2021, 11, 682445.	3.0	17
18	Challenges and advances for the treatment of renal cancer patients with brain metastases: From immunological background to upcoming clinical evidence on immune-checkpoint inhibitors. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 163, 103390.	4.6	10

#	ARTICLE	IF	CITATIONS
37	Therapeutic sequences in patients with grade 1~2 neuroendocrine tumors (NET): an observational multicenter study from the ELIOS group. <i>Endocrine</i> , 2019, 66, 417-424.	2.4	25
38	De-differentiated retroperitoneal large liposarcoma and laparoscopic treatment: Is it possible and safe? The first literature case report. <i>International Journal of Surgery Case Reports</i> , 2019, 57, 113-117.	0.6	14
39	One shot NEPA plus dexamethasone to prevent multiple-day chemotherapy in sarcoma patients. <i>Supportive Care in Cancer</i> , 2019, 27, 3593-3597.	2.3	10
40	Are Long Noncoding RNAs New Potential Biomarkers in Gastrointestinal Stromal Tumors (GISTs)? The Role of H19 and MALAT1. <i>Journal of Oncology</i> , 2019, 2019, 1-7.	1.4	17
41	Role of tumor-infiltrating lymphocytes in patients with solid tumors: Can a drop dig a stone?. <i>Cellular Immunology</i> , 2019, 343, 103753.	3.1	196
42	Soft tissue sarcomas in the precision medicine era: new advances in clinical practice and future perspectives. <i>Radiologia Medica</i> , 2019, 124, 259-265.	7.9	10
43	Activity and safety of temozolomide in advanced adrenocortical carcinoma patients. <i>European Journal of Endocrinology</i> , 2019, 181, 681-689.	4.1	32
44	Body Mass Index as a Risk Factor for Toxicities in Patients with Advanced Soft-Tissue Sarcoma Treated with Trabectedin. <i>Oncology</i> , 2018, 95, 1-7.	1.9	7
45	The diagnostic accuracy of circulating tumor DNA for the detection of EGFR-T790M mutation in NSCLC: a systematic review and meta-analysis. <i>Scientific Reports</i> , 2018, 8, 13379.	3.5	68
46	Imatinib rechallenge in patients with advanced gastrointestinal stromal tumors following progression with imatinib, sunitinib and regorafenib. <i>Therapeutic Advances in Medical Oncology</i> , 2018, 10, 175883591879462.	3.4	30
47	Anticancer therapy-induced vascular toxicity: VEGF inhibition and beyond. <i>International Journal of Cardiology</i> , 2017, 227, 11-17.	1.7	65
48	Personalization of regorafenib treatment in metastatic gastrointestinal stromal tumours in real-life clinical practice. <i>Therapeutic Advances in Medical Oncology</i> , 2017, 9, 731-739.	3.4	21
49	Liquid Biopsy in Gastrointestinal Stromal Tumor. <i>Current Clinical Pathology</i> , 2017, , 151-159.	0.0	1
50	Imatinib dose escalation versus sunitinib as a second line treatment in KIT exon 11 mutated GIST: a retrospective analysis. <i>Oncotarget</i> , 2016, 7, 69412-69419.	1.8	18
51	Beyond evidence-based data: scientific rationale and tumor behavior to drive sequential and personalized therapeutic strategies for the treatment of metastatic renal cell carcinoma. <i>Oncotarget</i> , 2016, 7, 21259-21271.	1.8	16
52	Bone metastases in patients with metastatic renal cell carcinoma: are they always associated with poor prognosis?. <i>Journal of Experimental and Clinical Cancer Research</i> , 2015, 34, 10.	9.0	69
53	Trabectedin-related liver toxicity in soft tissue sarcoma patients: Always a good reason to discontinue the treatment?. <i>Journal of Clinical Oncology</i> , 2014, 32, 10572-10572.	5.3	0
54	Natural History of Malignant Bone Disease in Renal Cancer: Final Results of an Italian Bone Metastasis Survey. <i>PLoS ONE</i> , 2013, 8, e83026.	2.4	70

#	ARTICLE	IF	CITATIONS
55	A Case of Squamocellular Uterine Cervix Carcinoma Metastatic to the Skin with Enterocutaneous Fistula. Tumori, 2006, 92, 264-266.	1.1	0